ALK-abello A/S Class B (($DK:ALK.B)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ALK-Abelló’s latest earnings call struck an upbeat tone as strong Q1 numbers, upgraded guidance, and pipeline progress outweighed operational and market-access challenges. Management pointed to broad-based growth in tablets and anaphylaxis products, solid cash generation, and key regulatory wins, while cautioning about rising costs, shipment phasing issues, and future pricing pressures.
Revenue and EBIT Growth
ALK reported a robust start to the year, with Q1 revenue rising 18% in local currencies to DKK 1.8 billion. Operating profit climbed 22% to DKK 570 million, lifting the EBIT margin to 32% from 31% and underscoring the earnings leverage from the company’s expanding allergy portfolio.
Tablet Sales Milestone
For the first time, tablet sales surpassed DKK 1 billion in a single quarter, cementing tablets as ALK’s growth engine. Tablet revenue grew about 26% in both Europe and North America, driven by strong demand for house-dust-mite and pollen tablets across key markets.
Improved Gross Margin and Cash Generation
Gross margin improved to 69%, up 2 percentage points year on year, supported by higher volumes and a favorable product mix toward tablets and anaphylaxis. Operating cash flow reached DKK 761 million and free cash flow DKK 671 million, giving the company ample financial flexibility for upcoming R&D and commercial investments.
Upgraded Full-Year Guidance
On the back of the strong quarter, ALK raised its full-year revenue growth outlook to 13%–16% in local currencies, up from 11%–15% previously. The company now targets an EBIT margin of around 26% for the year, slightly ahead of its long-term ambition of roughly 25%, despite rising capacity costs.
Strong Regional Performance — Europe & North America
Europe remained a powerhouse with revenue up 19%, supported by high double-digit tablet growth in Germany and France. North America delivered 16% revenue growth in local currencies, helped by surging tablet demand in Canada and early contributions from neffy co-promotion initiatives in the U.S.
Anaphylaxis and Other Product Strength
Sales of anaphylaxis and other products jumped 31% overall, with anaphylaxis alone soaring 84% in the quarter. Jext, ALK’s adrenaline auto-injector, benefited from higher replacement rates and tender wins, highlighting the strategic importance of the emergency treatment segment.
Peanut Allergy Phase II Success
The Phase II ALLIANCE trial in peanut allergy produced dose-dependent, statistically significant efficacy across multiple endpoints after six months of treatment. The candidate was described as safe and well tolerated, with low discontinuation and no treatment-related anaphylaxis or serious adverse events, paving the way for a planned Phase III trial expected to conclude in late 2026.
Regulatory Progress for EURneffy
ALK reported important regulatory advances for EURneffy, its intranasal epinephrine product, in key international markets. The European Commission approved the 1 mg dose for children aged four and over, while Canada cleared the 2 mg dose, with first launches expected in the second half of 2026 and shortly after summer, respectively.
Product Launch Rollouts and Prescriber Adoption
The company continued rolling out its pediatric tablet portfolio, with house-dust-mite tablets now available in 21 markets and tree pollen tablets in 13. More than 4,000 prescribers in directly served geographies have written prescriptions for children’s tablets, and about 20% of those doctors are new to ALK, broadening the prescriber base.
Increase in Capacity Costs
Capacity costs rose 23% in local currencies to DKK 658 million as ALK ramped up commercial resources and growth initiatives. While these investments support long-term expansion, they temporarily pressure operating leverage, with the capacity-cost-to-revenue ratio sitting at 37% in Q1.
International Tablet Decline and Shipment Phasing
Outside Europe and North America, tablet sales declined 17% in Q1, primarily due to shipment phasing rather than end-market demand. Reduced deliveries to Japan, amid capacity constraints and a standstill related to the Torii takeover, weighed on international figures and are expected to normalize later in the year.
Partner-Related Lower Margins Expected
Management warned that partner-related revenues, which carry lower margins, will increase as shipments to Japan and China resume and neffy volumes build. This shift in mix is expected to pull the gross margin back from the unusually high Q1 level and weigh slightly on the full-year margin profile.
Neffy Early-Stage Revenue and Market Access Hurdles
Neffy revenue in Q1 was modest and broadly in line with internal expectations, reflecting the early stage of the launch. Market access remains a key hurdle, with the U.K. requiring inclusion across dozens of local formularies and U.S. uptake constrained by access, leading to a gradual and uneven regional ramp.
Pricing and Rebate Regulatory Risk in Germany
ALK flagged a potential headwind from German healthcare policy, where lawmakers are considering an extra 3.5% discount from 2027 on top of the existing 7%. If implemented, the combined 10.5% rebate would pressure pricing in one of ALK’s key European markets, with uncertainty around how long such measures might last.
SLIT-drops Decline in France
Within the broader SLIT category, SLIT-drops performance was mixed, with France posting a decline that partly offset gains elsewhere in Europe. This dragged on the momentum of the SLIT line even as tablets continued to grow strongly, underlining ongoing shifts within ALK’s allergy portfolio.
Planned Increased R&D and Commercial Spend
The company signaled a step-up in investment for its pipeline and commercial rollouts, including the peanut allergy Phase III program and potential development of ALK-014. Combined with neffy launches and field-force expansion, these R&D and commercial costs are expected to rise notably and could depress margins in 2027–2028.
Uncertainty from Macroeconomic and Pricing Factors
ALK’s planning assumptions factor in macroeconomic and pricing risks, including possible price and rebate adjustments in multiple markets. The timing and scale of such pressures remain uncertain, and management cautioned that these variables could add volatility to revenue and earnings over the coming years.
Upgraded Guidance and Outlook
Looking ahead, ALK expects revenue growth of 13%–16% in local currencies this year, underpinned by double-digit tablet growth and solid demand in anaphylaxis and other products. The EBIT margin is guided at around 26%, with gross margin roughly in line with last year, stable capacity-cost ratios, and neffy’s financial contribution building more visibly from the second half of 2026 into 2027.
ALK’s earnings call painted the picture of a specialty pharma group moving confidently through its next growth phase, supported by strong Q1 execution and an increasingly differentiated allergy portfolio. While rising costs, pricing risks, and access challenges remain on the radar, upgraded guidance and late-stage pipeline assets give investors reasons to stay focused on the long-term upside.